MedDataX Logo

The Role of Histamine in Muscle Protein Synthesis Following Resistance Training

NCT ID: NCT06152497

Last Updated: 2023-12-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Blocking histamine H1/H2 receptors blunts chronic endurance training adaptations. The current study addresses the following research question: "What is the influence of histamine H1 signaling on training adaptations following ten weeks of resistance training in human skeletal muscle." Results from this study will yield more insights into the molecular mechanisms of adaptations to exercise training.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Histamine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel groups
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1: Placebo

Lactose

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral placebo

Resistance training

Intervention Type BEHAVIORAL

Resistance training: lower body exercise

H1 blockade: Telfast (180mg Fexofenadine)

H1: Telfast (180mg Fexofenadine)

Group Type EXPERIMENTAL

H1 blockade: Telfast: 180mg Fexofenadine

Intervention Type DRUG

H1 blockade: oral blockade with 180mg Fexofenadine

Resistance training

Intervention Type BEHAVIORAL

Resistance training: lower body exercise

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Oral placebo

Intervention Type DRUG

H1 blockade: Telfast: 180mg Fexofenadine

H1 blockade: oral blockade with 180mg Fexofenadine

Intervention Type DRUG

Resistance training

Resistance training: lower body exercise

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male
* 18-45 years
* Not to medium physically active

Exclusion Criteria

* Smoking
* Chronic disease
* High blood pressure
* Supplement or medication intake
* Seasonal allergies
* Vegetarian / vegan
* Resistance trained
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Research Foundation Flanders

OTHER

Sponsor Role collaborator

University Ghent

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wim Derave, Professor

Role: PRINCIPAL_INVESTIGATOR

University Ghent

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of movement and sports sciences, Ghent University, Belgium

Ghent, Oost-Vlaanderen, Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wim Derave, Professor

Role: CONTACT

Phone: 92646326

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Wim Derave, Professor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MPSH - ONZ-2023-0027

Identifier Type: -

Identifier Source: org_study_id